Excedrin Recall Issued for 433K Bottles Due to Poisoning Risk

Nearly half a million bottles of Excedrin are being recalled due a risk there may be puncture holes on the bottom, which may cause the pain medication to fall out and pose a child poisoning risk.

The U.S. Consumer Product Safety Commission (CPSC) announced the Excedrin recall on December 23, after determining certain bottles contain a puncture hole in the bottom, which may provide children with access to the pills.

The recall includes approximately 433,600 bottles of 50, 80, 100, 125, 200, 250 and 300-count bottles of Excedrin Migraine Caplets, Excedrin Migraine Geltabs, Excedrin Extra Strength Caplets, Excedrin PM Headache Caplets, and Excedrin Tension Headache Caplets manufactured in the United States by GSK Consumer Healthcare, of Warren, New Jersey.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

The products were sold at pharmacies, department stores, grocery stores, and hypermarkets nationwide and online from March 2018 through September 2020 for between $7 and $18.

According to the recall notice, the products were packaged in plastic bottles that contains a child-resistant cap, which is required by law under the Poison Prevention Packaging Act (PPPA) for any products containing aspirin and acetaminophen. However, GSK has identified certain lots of the Excedrin medications may contain a hole in the bottom of the bottle, which could allow pills or tablets of the container to be accessible to children, increasing the risk of a poisoning event.

The reasoning for the puncture hole in the pill bottles was not disclosed in the recall notice, and no Excedrin poisoning events have been reported to date.

The manufacturer is instructing consumers to inspect the bottom of the bottle immediately to determine if there is a hole, and to place the bottles out of sight and reach from children.

Customers who have a hole in the bottom of a bottle are being instructed to contact GSK Consumer Relations at 800-468-7746 for information on how to receive a prepaid shipping label and full refund. Bottles that do not have a hole may be kept and used as directed.

More than 400,000 reports of children being exposed to household cleaners and medications are reported annually to U.S. Poison Control Centers, resulting in tens of thousands of emergency room visits.

Health experts always recommend consumers be vigilant in practicing safe storage habits for household chemicals and prescription or OTC medications by keeping them behind safety locks or up high and out of sight from children, so as not to entice them to climb on furniture.


  • WhitneyJanuary 27, 2022 at 10:17 am

    Im looking to get in contact with someone about this issue. I was diagnosed with stage 5 kidney failure out the blue and as stated by my doc it was due to taking excedrin for my terrible migraines. Now i not only have to do dialysis everyday but i also have sarcoidosis and became a type 2 diabetic due to all the new meds i was put on due to my kidney failure from taking the excedrin.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted 2 days ago)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 4 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.